IPP Bureau
Zydus inks licensing, commercialisation pact with RK Pharma
By IPP Bureau - November 27, 2025
RK Pharma will manufacture and supply the finished product, while Zydus will be responsible for the NDA submission and commercialization of the product in the US
Dhoni joins Arth by Emcure to tackle iron deficiency on World Iron Deficiency Day
By IPP Bureau - November 27, 2025
FDA updates label for Sun Pharma’s UNLOXCYT, highlighting durable responses in advanced skin cancer
By IPP Bureau - November 27, 2025
The update reflects long-term clinical trial data showing that many patients with mCSCC or laCSCC experienced lasting responses
Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
By IPP Bureau - November 27, 2025
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Enlivex reports promising six-month data for Allocetra in knee osteoarthritis
By IPP Bureau - November 27, 2025
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
Cidara hits target enrollment for Phase 3 flu trial ahead of peak season
By IPP Bureau - November 27, 2025
CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents
Philips’ next-gen platform lets radiologists work anywhere, faster
By IPP Bureau - November 27, 2025
The viewer aims to help radiologists work smarter, faster, and more collaboratively, while reducing IT complexity and freeing up valuable clinical time
Glenmark Pharma gets VAI from FDA for Monroe facility
By IPP Bureau - November 27, 2025
The positive outcome clears the way for Glenmark to resume commercial manufacturing at the site
EU greenlights Dupixent for chronic urticaria, offering new hope to patients
By IPP Bureau - November 27, 2025
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response
By IPP Bureau - November 27, 2025
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
Valneva shifts French ops to Lyon
By IPP Bureau - November 27, 2025
Valneva will consolidate its French operations at its Lyon site and close its Nantes location
Gavi and UNICEF ink agreement to slash malaria vaccine price
By IPP Bureau - November 27, 2025
The deal, backed by Gavi and executed by UNICEF, could generate up to US$90 million in savings—enough to provide more than 30 million additional doses
Owlet taps OpenSynergy’s bluetooth tech to power next-gen baby monitor
By IPP Bureau - November 27, 2025
Owlet’s push comes as parents demand smarter, more dependable nursery tech
Otsuka files FDA application for first-in-class ADHD drug
By IPP Bureau - November 27, 2025
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
